Cancer is hard.But thereis hope.

We bring precision oncology into your hands, matching you with
clinical trials using AI-driven insights—no matter your cancer
type or stage.

nextrial.

How It Works

Four simple steps to find your match

Our AI-powered platform makes clinical trial discovery effortless and personalized.

1

Share Your Story

Share Your Story
Medical HistoryComplete
Diagnosis DetailsVerified
Treatment Preferences
• Location: Within 50 miles
• Phase: II, III
• Duration: 3-6 months
🔒 HIPAA-compliant encryption enabled
2

AI-Powered Matching

AI-Powered Matching
Analyzing profile...2.1s
RAG System ActiveReady
Database Query
→ Searching 2,847 active trials
→ Matching eligibility criteria
→ Evaluating location proximity
→ Ranking by compatibility
AI matching complete
3

Review Personalized Matches

Review Personalized Matches
12
Matches FoundSorted by score
Trial #NCT0489298% Match
Phase III • 15 miles • 6 months
Trial #NCT0512394% Match
Phase II • 22 miles • 4 months
Trial #NCT0475691% Match
Phase III • 8 miles • 5 months
4

Interactive Trial Mapping

Interactive Trial Mapping
Mapbox IntegrationLive
Global Trial Distribution
RegionRelative Density
California
9.9%
France
6.2%
China
3.9%
Florida
3.5%
Texas
3.0%
📍 1,000+ Active SitesPowered by Mapbox
Integrations

MCP Enabled.
Endless Possibilities.

Our Model Context Protocol (MCP) integration seamlessly connects external data sources to our RAG pipeline. By integrating ClinicalTrials.gov, FHIR-compliant patient records, vector databases via Supabase, PubMed research articles, and location services through Mapbox, all powered by Modal's serverless infrastructure for scalable AI inference, we provide comprehensive, real-time clinical trial matching powered by AI.

ClinicalTrials.gov
FHIR
Supabase
PubMed
Mapbox
Modal
NexTrial Logo
By The Numbers

Trained on thousands

0

Clinical Trials Indexed

Comprehensive database of active and recruiting trials

0

Patient Records Analyzed

Leveraging vast medical data for accurate matching

0%

Match Accuracy

AI-powered precision in trial recommendations